Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Dosing Underway for PIERRE Pivotal Study of ThecaFlex DRx System and Nusinersen
January 11th 2024The study investigates the potential benefits of ThecaFlex DRx System, an implantable intrathecal catheter, for patients with SMA treated with nusinersen, aiming to reduce the need for serial lumbar punctures and enhance the overall administration experience.
Dyne Reports Positive Phase 1/2 Data for Duchenne Agent DYNE-251
January 6th 2024After 6 months of treatment, once every 4-week administration of DYNE-251 reached levels of dystrophin expression, exon skipping, and percent dystrophin positive fibers that exceeded levels reported in a previous trial of eteplirsen, considered the standard of care.
Clinical Potential of AOC 1044 in Treating Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping
January 2nd 2024Steve Hughes, MD, chief medical officer at Avidity Biosciences, provided commentary on recently announced positive topline data for AOC 1044, an investigational agent for Duchenne muscular dystrophy.
Episode 105: Recapping Conversations in Neurology From 2023
December 29th 2023Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2023, with insights from Sharon Cohen, MD, FRCPC; Robert A. Hauser, MD, MBA; Alberto Espay, MD, PhD; Carolina Ferreira Atuesta, MD, MSc; and Natalie Goedeker, CPNP. [LISTEN TIME: minutes]